Literature DB >> 24421538

Dimethyl fumarate.

Dennis J Cada1, Terri L Levien2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The September 2013 monograph topics are trametinib, simeprevir, paroxetine mesylate, and empagliflozin. The DUE/MUE is on aripiprazole.

Entities:  

Year:  2013        PMID： 24421538      PMCID： PMC3847980          DOI： 10.1310/hpj4808-668

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  23 in total

1.  Multiple sclerosis review.

Authors:  Marvin M Goldenberg
Journal:  P T       Date:  2012-03

2.  Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.

Authors:  S Schilling; S Goelz; R Linker; F Luehder; R Gold
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 3.  Individualizing treatment goals and interventions for people with MS.

Authors:  Gavin Giovannoni; Robert W Rhoades
Journal:  Curr Opin Neurol       Date:  2012-02       Impact factor: 5.710

Review 4.  Immune mechanisms of new therapeutic strategies in MS: teriflunomide.

Authors:  Malte C Claussen; Thomas Korn
Journal:  Clin Immunol       Date:  2011-03-01       Impact factor: 3.969

5.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Authors:  Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

Review 6.  Pathophysiology of multiple sclerosis and the place of teriflunomide.

Authors:  R Gold; J S Wolinsky
Journal:  Acta Neurol Scand       Date:  2010-09-29       Impact factor: 3.209

7.  Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

Authors:  D Moharregh-Khiabani; R A Linker; R Gold; M Stangel
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

8.  Emerging multiple sclerosis oral therapies.

Authors:  Kottil W Rammohan; Jennifer Shoemaker
Journal:  Neurology       Date:  2010-01-05       Impact factor: 9.910

9.  Emerging disease-modifying therapies in multiple sclerosis.

Authors:  Jai Perumal; Omar Khan
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.972

10.  Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.

Authors:  Jan Thöne; Gisa Ellrichmann
Journal:  Drug Healthc Patient Saf       Date:  2013-02-26
View more
  7 in total

1.  Dimethyl Fumarate Blocks Tumor Necrosis Factor-Alpha-Driven Inflammation and Metabolic Rewiring in the Retinal Pigment Epithelium.

Authors:  Daisy Y Shu; Scott I Frank; Tessa C Fitch; Margarete M Karg; Erik R Butcher; Emmanuella Nnuji-John; Leo A Kim; Magali Saint-Geniez
Journal:  Front Mol Neurosci       Date:  2022-06-23       Impact factor: 6.261

Review 2.  Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options.

Authors:  Jasna Jancic; Blazo Nikolic; Nikola Ivancevic; Vesna Djuric; Ivan Zaletel; Dejan Stevanovic; Sasa Peric; John N van den Anker; Janko Samardzic
Journal:  Neurol Ther       Date:  2016-09-17

Review 3.  Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism.

Authors:  Agnieszka Loboda; Milena Damulewicz; Elzbieta Pyza; Alicja Jozkowicz; Jozef Dulak
Journal:  Cell Mol Life Sci       Date:  2016-04-21       Impact factor: 9.261

4.  Monomethyl Fumarate Protects the Retina From Light-Induced Retinopathy.

Authors:  Dan Jiang; Renee C Ryals; Samuel J Huang; Kyle K Weller; Hope E Titus; Bryan M Robb; Firas W Saad; Ribal A Salam; Hytham Hammad; Paul Yang; Daniel L Marks; Mark E Pennesi
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-03-01       Impact factor: 4.799

Review 5.  Role of dimethyl fumarate in the treatment of glioblastoma multiforme: A review article.

Authors:  Reza Ahmadi-Beni; Ali Najafi; Seyed Mehrdad Savar; Niayesh Mohebbi; Alireza Khoshnevisan
Journal:  Iran J Neurol       Date:  2019-07-06

6.  Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium.

Authors:  Ewa Szczesny-Malysiak; Marta Stojak; Roberto Campagna; Marek Grosicki; Marek Jamrozik; Patrycja Kaczara; Stefan Chlopicki
Journal:  Oxid Med Cell Longev       Date:  2020-10-14       Impact factor: 6.543

7.  Nrf2/ARE Activators Improve Memory in Aged Mice via Maintaining of Mitochondrial Quality Control of Brain and the Modulation of Gut Microbiome.

Authors:  Irina S Sadovnikova; Artem P Gureev; Daria A Ignatyeva; Maria V Gryaznova; Ekaterina V Chernyshova; Ekaterina P Krutskikh; Anastasia G Novikova; Vasily N Popov
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.